The activation of BRAF-V600E also results in phosphorylation of the inhibitor of kappa B (IκB) leading to its ubiquitin-proteasome-dependent degradation and the release of NF-κB that can now translocate to the nucleus and upregulate tumor-promoting and anti-apoptotic genes. Here, BRAF is linked to neoplasm.